Abstract
The SARS-CoV-2 vaccine BBV152/Covaxin is well-tolerated and was shown to be 77.8% efficacious against symptomatic and 93.4% efficacious against severe symptomatic COVID-19 disease in adults. Previous studies have shown that sera from Covaxin vaccinated individuals have neutralizing activity against B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), B.1.1.28 (Zeta), and B.1.617.1 (Kappa) SARS-CoV-2 variants. The B.1.1.529 variant (Omicron) recently emerged in November 2021 and has spread throughout the world. The Omicron variant has more than 30 mutations within the spike protein that could impact vaccine-mediated immunity. We used a live virus neutralization assay to evaluate the neutralizing activity against the Omicron variant of sera collected from subjects who received a booster dose (6-month after primary series last dose) of Covaxin. We found that sera from Covaxin boosted individuals showed neutralizing activity against D614G (vaccine strain), Delta, and Omicron variants. One hundred percent of boosted subjects showed neutralizing activity against the Delta variant while over 90% of boosted subjects showed neutralizing activity against the Omicron variant. These findings show that a booster dose of Covaxin can generate robust neutralizing antibody responses against the Omicron variant.
Competing Interest Statement
M.S.S has an advisory role with Ocugen and Moderna.
Clinical Trial
NCT04471519
Funding Statement
This work was sponsored by Ocugen, Inc., Malvern, USA, and serum samples were provided by Bharat Biotech India Limited, Hyderabad, India.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
ECR/303/Inst/AP/2013/RR-19 of Nizam's Institute of Medical Sciences, Hyderabad gave ethical approval for this work 2.ECR/495/Inst/HR/2013/RR-20 of Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences Rohtak gave ethical approval for this work 3.ECR/1387/Inst/BR/2020 of All India Medical Sciences (AIIMS), Patna gave ethical approval for this work 4.ECR/902/Inst/GA/2018 of Redkar Hospital and Research center, Goa gave ethical approval for this work 5.ECR/1374/Inst/MH/2020 of Gillurkar Multispecialty Hospitals, Nagpur gave ethical approval for this work 6.ECR/1017/Inst/UP/2017/RR-21 of Prakhar Hospital Private Limited, Kanpur gave ethical approval for this work 7.ECR/431/Inst/TN/2013/RR-19 of SRM Medical College Hospital & Research Center, Tamil Nadu gave ethical approval for this work 8.ECR/1242/Inst/KA/2019 of Jeevan Rekha Hospital, Belagavi gave ethical approval for this work 9.ECR/538/Inst/DL/2014/RR-20 of All India Medical Sciences, New Delhi gave ethical approval for this work. Ethical approval was granted.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
